Bloomberg Intelligence's Duane Wright on Health Equity in Dermatology

The video emphasizes the importance of improving diversity in clinical trials to ensure new therapies benefit the entire population. It highlights the current underrepresentation of minority groups and explores factors contributing to this issue. Solutions include regulatory changes and decentralizing trials using technology like telemedicine and wearables. These approaches can enhance data collection, reduce patient burden, and improve trial participation. The video also discusses the growth of digital clinical measures and their potential to advance research in various medical fields.

What is one of the main reasons for the underrepresentation of Black and Hispanic populations in clinical trials?

• Lack of interest in medical research

• Trial awareness and site location issues

• Higher participation in other types of research

• Overrepresentation in other demographic studies

What role do regulators and policymakers play in improving diversity in clinical trials?

• They develop regulations requiring inclusivity

• They conduct all clinical trials themselves

• They ignore diversity issues in trials

• They fund only trials with diverse participants

How can decentralizing clinical trials help improve diversity?

• By utilizing telemedicine and local clinics

• By using only traditional trial sites

• By limiting trials to urban areas

• By excluding digital technologies

What is a benefit of using wearables and digital technologies in clinical trials?

• Decreased data accuracy

• Increased patient travel requirements

• Reduced patient retention rates

• Continuous monitoring of participants

What has been the growth rate of trials collecting digital endpoints since 2013?

• 25% compound annual growth rate

• 35% compound annual growth rate

• 55% compound annual growth rate

• 45% compound annual growth rate